These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 37546400)

  • 21. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
    Amaria RN; Prieto PA; Tetzlaff MT; Reuben A; Andrews MC; Ross MI; Glitza IC; Cormier J; Hwu WJ; Tawbi HA; Patel SP; Lee JE; Gershenwald JE; Spencer CN; Gopalakrishnan V; Bassett R; Simpson L; Mouton R; Hudgens CW; Zhao L; Zhu H; Cooper ZA; Wani K; Lazar A; Hwu P; Diab A; Wong MK; McQuade JL; Royal R; Lucci A; Burton EM; Reddy S; Sharma P; Allison J; Futreal PA; Woodman SE; Davies MA; Wargo JA
    Lancet Oncol; 2018 Feb; 19(2):181-193. PubMed ID: 29361468
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful re-challenge of dabrafenib-trametinib combination therapy in advanced
    Xue Y; Ren Y; Yan B; Li Z; Huang C
    Ann Transl Med; 2022 Sep; 10(18):1029. PubMed ID: 36267742
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Response of Advanced Lung Adenocarcinoma with Class III BRAF G466V Missense Mutation to Dabrafenib and Trametinib: A Case Report.
    Fang R; Xu S; Gong J; Liao Z
    Onco Targets Ther; 2024; 17():27-31. PubMed ID: 38283732
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
    Long GV; Stroyakovskiy D; Gogas H; Levchenko E; de Braud F; Larkin J; Garbe C; Jouary T; Hauschild A; Grob JJ; Chiarion Sileni V; Lebbe C; Mandalà M; Millward M; Arance A; Bondarenko I; Haanen JB; Hansson J; Utikal J; Ferraresi V; Kovalenko N; Mohr P; Probachai V; Schadendorf D; Nathan P; Robert C; Ribas A; DeMarini DJ; Irani JG; Casey M; Ouellet D; Martin AM; Le N; Patel K; Flaherty K
    N Engl J Med; 2014 Nov; 371(20):1877-88. PubMed ID: 25265492
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Complete response of metastatic
    Lee SJ; Song SY; Kim MK; Na HG; Bae CH; Kim YD; Choi YS
    World J Clin Cases; 2023 Sep; 11(27):6664-6669. PubMed ID: 37900238
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of Dabrafenib Plus Trametinib Combination in Patients with
    Auliac JB; Bayle S; Do P; Le Garff G; Roa M; Falchero L; Huchot E; Quéré G; Jeannin G; Métivier AC; Hobeika J; Guisier F; Chouaid C
    Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33276639
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.
    Subbiah V; Kreitman RJ; Wainberg ZA; Cho JY; Schellens JHM; Soria JC; Wen PY; Zielinski C; Cabanillas ME; Urbanowitz G; Mookerjee B; Wang D; Rangwala F; Keam B
    J Clin Oncol; 2018 Jan; 36(1):7-13. PubMed ID: 29072975
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rechallenge with dabrafenib plus trametinib in anaplastic thyroid cancer: A case report and review of literature.
    Arıkan R; Telli TA; Demircan NC; Başoğlu T; Ercelep Ö; Atasoy BM; Özgüven S; Dane F; Yumuk PF
    Curr Probl Cancer; 2021 Apr; 45(2):100668. PubMed ID: 33127167
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful Treatment with Dabrafenib/Trametinib of a Malignantly Transformed and Metastasized BRAF V600E Mutant Pleiomorphic Xanthoastrocytoma: A Case Report and Review of the Literature.
    Vermeulen E; Vander Mijnsbrugge AS; Brock S; Vaeyens F; Dirven I; Ciçek A; Marcelis W; Klein S; Bruneau M; Neyns B; Duerinck J
    Case Rep Oncol; 2024; 17(1):10-16. PubMed ID: 38179547
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ongoing complete response after treatment cessation with dabrafenib, trametinib, and cetuximab as third-line treatment in a patient with advanced BRAF
    Piringer G; Decker J; Trommet V; Kühr T; Heibl S; Dörfler K; Thaler J
    Front Oncol; 2023; 13():1166545. PubMed ID: 37213293
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of
    Gowda S; Sandow L; Heinrich MC
    J Gastrointest Oncol; 2024 Apr; 15(2):788-793. PubMed ID: 38756640
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Redifferentiation of BRAF V600E-Mutated Radioiodine Refractory Metastatic Papillary Thyroid Cancer After Treatment With Dabrafenib and Trametinib.
    Jafri S; Yaqub A
    Cureus; 2021 Aug; 13(8):e17488. PubMed ID: 34595070
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAF
    Facchinetti F; Lacroix L; Mezquita L; Scoazec JY; Loriot Y; Tselikas L; Gazzah A; Rouleau E; Adam J; Michiels S; Massard C; André F; Olaussen KA; Vassal G; Howarth K; Besse B; Soria JC; Friboulet L; Planchard D
    Eur J Cancer; 2020 Jun; 132():211-223. PubMed ID: 32388065
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cerebral infarction after treatment with dabrafenib plus trametinib for BRAF-V600E-positive non-small cell lung cancer: A case report.
    Taniguchi Y; Tamiya A; Yanagisawa A; Shimaya M; Kawakami M; Inagaki Y; Saijo N; Matsuda Y; Okishio K
    Thorac Cancer; 2023 May; 14(13):1201-1203. PubMed ID: 36935386
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy.
    Williams CB; McMahon C; Ali SM; Abramovitz M; Williams KA; Klein J; McKean H; Yelensky R; George TJ; Elvin JA; Soman S; Lipson D; Chmielecki J; Morosini D; Miller VA; Stephens PJ; Ross JS; Leyland-Jones B
    Onco Targets Ther; 2015; 8():3561-4. PubMed ID: 26664139
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic Effect of Combined Dabrafenib and Trametinib Treatment of BRAF V600E-Mutated Primary Squamous Cell Carcinoma of the Thyroid: A Case Report.
    Brandenburg T; Muchalla P; Theurer S; Schmid KW; Führer D
    Eur Thyroid J; 2021 Nov; 10(6):511-516. PubMed ID: 34956922
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined Lorlatinib, Dabrafenib, and Trametinib Treatment for
    Li D; Liu J; Zhang X; Han J; Jin H; Wang L; Feng L; Fan Z; Zuo J; Wang Y
    Cancer Manag Res; 2022; 14():3175-3179. PubMed ID: 36411743
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Durable Response to Combined Dabrafenib and Trametinib in a Patient With BRAF K601E Mutation-Positive Lung Adenocarcinoma: A Case Report.
    Su PL; Lin CY; Chen YL; Chen WL; Lin CC; Su WC
    JTO Clin Res Rep; 2021 Aug; 2(8):100202. PubMed ID: 34590045
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis.
    Planchard D; Besse B; Groen HJM; Hashemi SMS; Mazieres J; Kim TM; Quoix E; Souquet PJ; Barlesi F; Baik C; Villaruz LC; Kelly RJ; Zhang S; Tan M; Gasal E; Santarpia L; Johnson BE
    J Thorac Oncol; 2022 Jan; 17(1):103-115. PubMed ID: 34455067
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Response to the Combination of Osimertinib, Dabrafenib, and Trametinib in Leptomeningitis From
    Valet O; Swalduz A; Boussageon M; Buisson A; Avrillon V; Mastroïanni B; Pérol M
    JTO Clin Res Rep; 2021 Jun; 2(6):100192. PubMed ID: 34590033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.